EXP MOL MED 润色咨询

EXPERIMENTAL AND MOLECULAR MEDICINE

出版年份:1996 年文章数:1065 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:0.6% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1200306, encodeId=6f4c12003065f, content=收到了主题为Associate Editor Assigned的邮件,这说明到哪一阶段了??送审了没有啊???, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6cb35421011, createdName=ms1000001879726925, createdTime=Mon Mar 07 19:21:43 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106816, encodeId=035d210681669, content=请问最近有人投这个杂志吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ae45165239, createdName=146c5a24m26(暂无昵称), createdTime=Tue Dec 20 15:04:05 CST 2022, time=2022-12-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1233810, encodeId=d04112338107a, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:细胞生物;动物实验;分子医学<br>经验分享:虽然被拒了,但是感觉速度挺快的,投稿后18天得到消息。大家感兴趣的我觉得可以一试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e83e5311024, createdName=148893c2m57(暂无昵称), createdTime=Thu Jul 21 12:34:23 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100901, encodeId=8a632100901b2, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:请问这个是送审,还是还在编辑部,还没到编辑手里?有的人说没有AE assigned,有的说收到邮件了<br>Stage Start Date<br>Under Review 12th Nov 22 00:30:15<br>Author Approved Converted Files 12th Nov 22 00:30:15<br>Preliminary Manuscript Data Submitted 11th Nov 22 22:23:58, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/9d391e0b1cd74e869f11d621441146a1/0f85d4b8f25545bc8cd6ff7d737de80d.jpg, createdBy=8aaa108952, createdName=JayNi, createdTime=Wed Nov 16 16:18:50 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234254, encodeId=7a0d123425458, content=审稿速度:12.0 | 投稿命中率:25.0<br>经验分享:21年10月投出初稿,第一轮外审太慢了,用了5个月。期间圣诞节、新年,再加上全球疫情,我们没有催稿,只能耐着性子等待:<br><br>-2021年10月14日 Preliminary Manuscript Data Submitted<br>-2021年10月15日 Author Approved Converted Files<br>-2021年10月15日 Under Review<br>-2022年03月16日 Decision Made<br>-2022年03月16日 Decision Sent to Author<br><br>第二年3月份,审稿意见回来了,大修。其中一个审稿人疑虑比较多,对我们发现的新现象持有怀疑看法,认为证据不充足,15条大意见条条有针对性;另外的审稿人稍微温和点,总体上肯定了文章的创新性,但是修改意见也不少。主编给了3个月大修时间。<br><br>几个主要作者碰头开了几次小组讨论会,制定了补试验方案,两个博士作为主力,几个硕士辅助,一直扎扎实实补试验两个月后发现deadline不够了,又向杂志申请延期1个月。三个月补完试验,一个月修改文章、图片、Response letter。我们的修回信(42页)长度超过了文章(38页)长度了,内容非常丰满,证据可靠,图片漂亮,方法全面,当时自己都觉得文章质量大幅提升,要是不接受可以投15分以上杂志了。在补试验阶段,实验材料和测试成本就花了好多w。<br><br>22年七月份投出,结果审稿人很满意,第二轮只用17天,所有审稿人均认为可以直接接受。<br><br>-2022年07月02日 Author Approved Converted Files<br>-2022年07月02日 Under Review<br>-2022年07月19日 Decision Made<br>-2022年07月19日 Decision Sent to Author<br>-2022年07月19日 With NPG, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/21/1b8a115bb4bd3136efd4521b4b663fd0.jpg, createdBy=68f11698384, createdName=Lewisrat, createdTime=Sat Jul 23 14:39:07 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085622, encodeId=739e108562226, content=10.18投稿 10.23改了一些格式重新提交, un de r review 10.26发邮件说有消息会通知 12.28状态栏出现空白 12.29又是Under Revi ew 😂稍微有点慢,这是刚送外审么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dac05542334, createdName=ms4000000644050235, createdTime=Thu Dec 30 00:25:19 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237441, encodeId=7539123e441a7, content=偏重的研究方向:细胞生物;分子医学<br>经验分享:Emm有人拒稿过吗?多久拒稿啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Mon Aug 08 22:00:09 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118088, encodeId=2339211808828, content=Research Square上能看到审稿进度。我1月31日投稿,2月17日分配编辑,3月2日邀请审稿人,邀请了两个,3月6日显示已经收到两个审稿意见。希望有个好结果🙏🏻🙏🏻🙏🏻🙏🏻, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc388334751, createdName=ms1000000326683554, createdTime=Tue Mar 07 10:55:10 CST 2023, time=2023-03-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2155649, encodeId=4f22215564929, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:生物大分子;siRNA;基础医学<br>经验分享:Stage Start Date<br>Under Review 22nd Aug 23 09:29:31<br>Author Approved Converted Files 22nd Aug 23 09:29:31<br>Preliminary Manuscript Data Submitted 22nd Aug 23 04:02:20, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af918292843, createdName=ms6000000371699092, createdTime=Fri Sep 01 20:45:42 CST 2023, time=2023-09-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1248910, encodeId=61a5124891084, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:这个杂志不是一般的慢,8月1号投稿,8月15号时候收到Associate Editor Assigned的主题邮件,到现在都没消息,都不知道送审没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0876145252, createdName=ms8000000926448182, createdTime=Wed Sep 14 17:54:42 CST 2022, time=2022-09-14, status=1, ipAttribution=)]
    2022-03-07 ms1000001879726925

    收到了主题为Associate Editor Assigned的邮件,这说明到哪一阶段了??送审了没有啊???

    22

    展开22条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1200306, encodeId=6f4c12003065f, content=收到了主题为Associate Editor Assigned的邮件,这说明到哪一阶段了??送审了没有啊???, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6cb35421011, createdName=ms1000001879726925, createdTime=Mon Mar 07 19:21:43 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106816, encodeId=035d210681669, content=请问最近有人投这个杂志吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ae45165239, createdName=146c5a24m26(暂无昵称), createdTime=Tue Dec 20 15:04:05 CST 2022, time=2022-12-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1233810, encodeId=d04112338107a, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:细胞生物;动物实验;分子医学<br>经验分享:虽然被拒了,但是感觉速度挺快的,投稿后18天得到消息。大家感兴趣的我觉得可以一试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e83e5311024, createdName=148893c2m57(暂无昵称), createdTime=Thu Jul 21 12:34:23 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100901, encodeId=8a632100901b2, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:请问这个是送审,还是还在编辑部,还没到编辑手里?有的人说没有AE assigned,有的说收到邮件了<br>Stage Start Date<br>Under Review 12th Nov 22 00:30:15<br>Author Approved Converted Files 12th Nov 22 00:30:15<br>Preliminary Manuscript Data Submitted 11th Nov 22 22:23:58, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/9d391e0b1cd74e869f11d621441146a1/0f85d4b8f25545bc8cd6ff7d737de80d.jpg, createdBy=8aaa108952, createdName=JayNi, createdTime=Wed Nov 16 16:18:50 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234254, encodeId=7a0d123425458, content=审稿速度:12.0 | 投稿命中率:25.0<br>经验分享:21年10月投出初稿,第一轮外审太慢了,用了5个月。期间圣诞节、新年,再加上全球疫情,我们没有催稿,只能耐着性子等待:<br><br>-2021年10月14日 Preliminary Manuscript Data Submitted<br>-2021年10月15日 Author Approved Converted Files<br>-2021年10月15日 Under Review<br>-2022年03月16日 Decision Made<br>-2022年03月16日 Decision Sent to Author<br><br>第二年3月份,审稿意见回来了,大修。其中一个审稿人疑虑比较多,对我们发现的新现象持有怀疑看法,认为证据不充足,15条大意见条条有针对性;另外的审稿人稍微温和点,总体上肯定了文章的创新性,但是修改意见也不少。主编给了3个月大修时间。<br><br>几个主要作者碰头开了几次小组讨论会,制定了补试验方案,两个博士作为主力,几个硕士辅助,一直扎扎实实补试验两个月后发现deadline不够了,又向杂志申请延期1个月。三个月补完试验,一个月修改文章、图片、Response letter。我们的修回信(42页)长度超过了文章(38页)长度了,内容非常丰满,证据可靠,图片漂亮,方法全面,当时自己都觉得文章质量大幅提升,要是不接受可以投15分以上杂志了。在补试验阶段,实验材料和测试成本就花了好多w。<br><br>22年七月份投出,结果审稿人很满意,第二轮只用17天,所有审稿人均认为可以直接接受。<br><br>-2022年07月02日 Author Approved Converted Files<br>-2022年07月02日 Under Review<br>-2022年07月19日 Decision Made<br>-2022年07月19日 Decision Sent to Author<br>-2022年07月19日 With NPG, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/21/1b8a115bb4bd3136efd4521b4b663fd0.jpg, createdBy=68f11698384, createdName=Lewisrat, createdTime=Sat Jul 23 14:39:07 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085622, encodeId=739e108562226, content=10.18投稿 10.23改了一些格式重新提交, un de r review 10.26发邮件说有消息会通知 12.28状态栏出现空白 12.29又是Under Revi ew 😂稍微有点慢,这是刚送外审么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dac05542334, createdName=ms4000000644050235, createdTime=Thu Dec 30 00:25:19 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237441, encodeId=7539123e441a7, content=偏重的研究方向:细胞生物;分子医学<br>经验分享:Emm有人拒稿过吗?多久拒稿啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Mon Aug 08 22:00:09 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118088, encodeId=2339211808828, content=Research Square上能看到审稿进度。我1月31日投稿,2月17日分配编辑,3月2日邀请审稿人,邀请了两个,3月6日显示已经收到两个审稿意见。希望有个好结果🙏🏻🙏🏻🙏🏻🙏🏻, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc388334751, createdName=ms1000000326683554, createdTime=Tue Mar 07 10:55:10 CST 2023, time=2023-03-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2155649, encodeId=4f22215564929, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:生物大分子;siRNA;基础医学<br>经验分享:Stage Start Date<br>Under Review 22nd Aug 23 09:29:31<br>Author Approved Converted Files 22nd Aug 23 09:29:31<br>Preliminary Manuscript Data Submitted 22nd Aug 23 04:02:20, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af918292843, createdName=ms6000000371699092, createdTime=Fri Sep 01 20:45:42 CST 2023, time=2023-09-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1248910, encodeId=61a5124891084, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:这个杂志不是一般的慢,8月1号投稿,8月15号时候收到Associate Editor Assigned的主题邮件,到现在都没消息,都不知道送审没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0876145252, createdName=ms8000000926448182, createdTime=Wed Sep 14 17:54:42 CST 2022, time=2022-09-14, status=1, ipAttribution=)]
    2022-12-20 146c5a24m26(暂无昵称) 来自广东省

    请问最近有人投这个杂志吗?

    13

    展开13条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1200306, encodeId=6f4c12003065f, content=收到了主题为Associate Editor Assigned的邮件,这说明到哪一阶段了??送审了没有啊???, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6cb35421011, createdName=ms1000001879726925, createdTime=Mon Mar 07 19:21:43 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106816, encodeId=035d210681669, content=请问最近有人投这个杂志吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ae45165239, createdName=146c5a24m26(暂无昵称), createdTime=Tue Dec 20 15:04:05 CST 2022, time=2022-12-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1233810, encodeId=d04112338107a, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:细胞生物;动物实验;分子医学<br>经验分享:虽然被拒了,但是感觉速度挺快的,投稿后18天得到消息。大家感兴趣的我觉得可以一试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e83e5311024, createdName=148893c2m57(暂无昵称), createdTime=Thu Jul 21 12:34:23 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100901, encodeId=8a632100901b2, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:请问这个是送审,还是还在编辑部,还没到编辑手里?有的人说没有AE assigned,有的说收到邮件了<br>Stage Start Date<br>Under Review 12th Nov 22 00:30:15<br>Author Approved Converted Files 12th Nov 22 00:30:15<br>Preliminary Manuscript Data Submitted 11th Nov 22 22:23:58, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/9d391e0b1cd74e869f11d621441146a1/0f85d4b8f25545bc8cd6ff7d737de80d.jpg, createdBy=8aaa108952, createdName=JayNi, createdTime=Wed Nov 16 16:18:50 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234254, encodeId=7a0d123425458, content=审稿速度:12.0 | 投稿命中率:25.0<br>经验分享:21年10月投出初稿,第一轮外审太慢了,用了5个月。期间圣诞节、新年,再加上全球疫情,我们没有催稿,只能耐着性子等待:<br><br>-2021年10月14日 Preliminary Manuscript Data Submitted<br>-2021年10月15日 Author Approved Converted Files<br>-2021年10月15日 Under Review<br>-2022年03月16日 Decision Made<br>-2022年03月16日 Decision Sent to Author<br><br>第二年3月份,审稿意见回来了,大修。其中一个审稿人疑虑比较多,对我们发现的新现象持有怀疑看法,认为证据不充足,15条大意见条条有针对性;另外的审稿人稍微温和点,总体上肯定了文章的创新性,但是修改意见也不少。主编给了3个月大修时间。<br><br>几个主要作者碰头开了几次小组讨论会,制定了补试验方案,两个博士作为主力,几个硕士辅助,一直扎扎实实补试验两个月后发现deadline不够了,又向杂志申请延期1个月。三个月补完试验,一个月修改文章、图片、Response letter。我们的修回信(42页)长度超过了文章(38页)长度了,内容非常丰满,证据可靠,图片漂亮,方法全面,当时自己都觉得文章质量大幅提升,要是不接受可以投15分以上杂志了。在补试验阶段,实验材料和测试成本就花了好多w。<br><br>22年七月份投出,结果审稿人很满意,第二轮只用17天,所有审稿人均认为可以直接接受。<br><br>-2022年07月02日 Author Approved Converted Files<br>-2022年07月02日 Under Review<br>-2022年07月19日 Decision Made<br>-2022年07月19日 Decision Sent to Author<br>-2022年07月19日 With NPG, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/21/1b8a115bb4bd3136efd4521b4b663fd0.jpg, createdBy=68f11698384, createdName=Lewisrat, createdTime=Sat Jul 23 14:39:07 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085622, encodeId=739e108562226, content=10.18投稿 10.23改了一些格式重新提交, un de r review 10.26发邮件说有消息会通知 12.28状态栏出现空白 12.29又是Under Revi ew 😂稍微有点慢,这是刚送外审么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dac05542334, createdName=ms4000000644050235, createdTime=Thu Dec 30 00:25:19 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237441, encodeId=7539123e441a7, content=偏重的研究方向:细胞生物;分子医学<br>经验分享:Emm有人拒稿过吗?多久拒稿啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Mon Aug 08 22:00:09 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118088, encodeId=2339211808828, content=Research Square上能看到审稿进度。我1月31日投稿,2月17日分配编辑,3月2日邀请审稿人,邀请了两个,3月6日显示已经收到两个审稿意见。希望有个好结果🙏🏻🙏🏻🙏🏻🙏🏻, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc388334751, createdName=ms1000000326683554, createdTime=Tue Mar 07 10:55:10 CST 2023, time=2023-03-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2155649, encodeId=4f22215564929, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:生物大分子;siRNA;基础医学<br>经验分享:Stage Start Date<br>Under Review 22nd Aug 23 09:29:31<br>Author Approved Converted Files 22nd Aug 23 09:29:31<br>Preliminary Manuscript Data Submitted 22nd Aug 23 04:02:20, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af918292843, createdName=ms6000000371699092, createdTime=Fri Sep 01 20:45:42 CST 2023, time=2023-09-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1248910, encodeId=61a5124891084, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:这个杂志不是一般的慢,8月1号投稿,8月15号时候收到Associate Editor Assigned的主题邮件,到现在都没消息,都不知道送审没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0876145252, createdName=ms8000000926448182, createdTime=Wed Sep 14 17:54:42 CST 2022, time=2022-09-14, status=1, ipAttribution=)]
    2022-07-21 148893c2m57(暂无昵称)

    审稿速度:1.0 | 投稿命中率:25.0
    偏重的研究方向:细胞生物;动物实验;分子医学
    经验分享:虽然被拒了,但是感觉速度挺快的,投稿后18天得到消息。大家感兴趣的我觉得可以一试

    13

    展开13条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1200306, encodeId=6f4c12003065f, content=收到了主题为Associate Editor Assigned的邮件,这说明到哪一阶段了??送审了没有啊???, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6cb35421011, createdName=ms1000001879726925, createdTime=Mon Mar 07 19:21:43 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106816, encodeId=035d210681669, content=请问最近有人投这个杂志吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ae45165239, createdName=146c5a24m26(暂无昵称), createdTime=Tue Dec 20 15:04:05 CST 2022, time=2022-12-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1233810, encodeId=d04112338107a, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:细胞生物;动物实验;分子医学<br>经验分享:虽然被拒了,但是感觉速度挺快的,投稿后18天得到消息。大家感兴趣的我觉得可以一试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e83e5311024, createdName=148893c2m57(暂无昵称), createdTime=Thu Jul 21 12:34:23 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100901, encodeId=8a632100901b2, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:请问这个是送审,还是还在编辑部,还没到编辑手里?有的人说没有AE assigned,有的说收到邮件了<br>Stage Start Date<br>Under Review 12th Nov 22 00:30:15<br>Author Approved Converted Files 12th Nov 22 00:30:15<br>Preliminary Manuscript Data Submitted 11th Nov 22 22:23:58, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/9d391e0b1cd74e869f11d621441146a1/0f85d4b8f25545bc8cd6ff7d737de80d.jpg, createdBy=8aaa108952, createdName=JayNi, createdTime=Wed Nov 16 16:18:50 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234254, encodeId=7a0d123425458, content=审稿速度:12.0 | 投稿命中率:25.0<br>经验分享:21年10月投出初稿,第一轮外审太慢了,用了5个月。期间圣诞节、新年,再加上全球疫情,我们没有催稿,只能耐着性子等待:<br><br>-2021年10月14日 Preliminary Manuscript Data Submitted<br>-2021年10月15日 Author Approved Converted Files<br>-2021年10月15日 Under Review<br>-2022年03月16日 Decision Made<br>-2022年03月16日 Decision Sent to Author<br><br>第二年3月份,审稿意见回来了,大修。其中一个审稿人疑虑比较多,对我们发现的新现象持有怀疑看法,认为证据不充足,15条大意见条条有针对性;另外的审稿人稍微温和点,总体上肯定了文章的创新性,但是修改意见也不少。主编给了3个月大修时间。<br><br>几个主要作者碰头开了几次小组讨论会,制定了补试验方案,两个博士作为主力,几个硕士辅助,一直扎扎实实补试验两个月后发现deadline不够了,又向杂志申请延期1个月。三个月补完试验,一个月修改文章、图片、Response letter。我们的修回信(42页)长度超过了文章(38页)长度了,内容非常丰满,证据可靠,图片漂亮,方法全面,当时自己都觉得文章质量大幅提升,要是不接受可以投15分以上杂志了。在补试验阶段,实验材料和测试成本就花了好多w。<br><br>22年七月份投出,结果审稿人很满意,第二轮只用17天,所有审稿人均认为可以直接接受。<br><br>-2022年07月02日 Author Approved Converted Files<br>-2022年07月02日 Under Review<br>-2022年07月19日 Decision Made<br>-2022年07月19日 Decision Sent to Author<br>-2022年07月19日 With NPG, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/21/1b8a115bb4bd3136efd4521b4b663fd0.jpg, createdBy=68f11698384, createdName=Lewisrat, createdTime=Sat Jul 23 14:39:07 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085622, encodeId=739e108562226, content=10.18投稿 10.23改了一些格式重新提交, un de r review 10.26发邮件说有消息会通知 12.28状态栏出现空白 12.29又是Under Revi ew 😂稍微有点慢,这是刚送外审么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dac05542334, createdName=ms4000000644050235, createdTime=Thu Dec 30 00:25:19 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237441, encodeId=7539123e441a7, content=偏重的研究方向:细胞生物;分子医学<br>经验分享:Emm有人拒稿过吗?多久拒稿啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Mon Aug 08 22:00:09 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118088, encodeId=2339211808828, content=Research Square上能看到审稿进度。我1月31日投稿,2月17日分配编辑,3月2日邀请审稿人,邀请了两个,3月6日显示已经收到两个审稿意见。希望有个好结果🙏🏻🙏🏻🙏🏻🙏🏻, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc388334751, createdName=ms1000000326683554, createdTime=Tue Mar 07 10:55:10 CST 2023, time=2023-03-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2155649, encodeId=4f22215564929, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:生物大分子;siRNA;基础医学<br>经验分享:Stage Start Date<br>Under Review 22nd Aug 23 09:29:31<br>Author Approved Converted Files 22nd Aug 23 09:29:31<br>Preliminary Manuscript Data Submitted 22nd Aug 23 04:02:20, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af918292843, createdName=ms6000000371699092, createdTime=Fri Sep 01 20:45:42 CST 2023, time=2023-09-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1248910, encodeId=61a5124891084, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:这个杂志不是一般的慢,8月1号投稿,8月15号时候收到Associate Editor Assigned的主题邮件,到现在都没消息,都不知道送审没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0876145252, createdName=ms8000000926448182, createdTime=Wed Sep 14 17:54:42 CST 2022, time=2022-09-14, status=1, ipAttribution=)]
    2022-11-16 JayNi

    审稿速度:3.0 | 投稿命中率:50.0
    经验分享:请问这个是送审,还是还在编辑部,还没到编辑手里?有的人说没有AE assigned,有的说收到邮件了
    Stage Start Date
    Under Review 12th Nov 22 00:30:15
    Author Approved Converted Files 12th Nov 22 00:30:15
    Preliminary Manuscript Data Submitted 11th Nov 22 22:23:58

    12

    展开12条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1200306, encodeId=6f4c12003065f, content=收到了主题为Associate Editor Assigned的邮件,这说明到哪一阶段了??送审了没有啊???, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6cb35421011, createdName=ms1000001879726925, createdTime=Mon Mar 07 19:21:43 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106816, encodeId=035d210681669, content=请问最近有人投这个杂志吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ae45165239, createdName=146c5a24m26(暂无昵称), createdTime=Tue Dec 20 15:04:05 CST 2022, time=2022-12-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1233810, encodeId=d04112338107a, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:细胞生物;动物实验;分子医学<br>经验分享:虽然被拒了,但是感觉速度挺快的,投稿后18天得到消息。大家感兴趣的我觉得可以一试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e83e5311024, createdName=148893c2m57(暂无昵称), createdTime=Thu Jul 21 12:34:23 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100901, encodeId=8a632100901b2, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:请问这个是送审,还是还在编辑部,还没到编辑手里?有的人说没有AE assigned,有的说收到邮件了<br>Stage Start Date<br>Under Review 12th Nov 22 00:30:15<br>Author Approved Converted Files 12th Nov 22 00:30:15<br>Preliminary Manuscript Data Submitted 11th Nov 22 22:23:58, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/9d391e0b1cd74e869f11d621441146a1/0f85d4b8f25545bc8cd6ff7d737de80d.jpg, createdBy=8aaa108952, createdName=JayNi, createdTime=Wed Nov 16 16:18:50 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234254, encodeId=7a0d123425458, content=审稿速度:12.0 | 投稿命中率:25.0<br>经验分享:21年10月投出初稿,第一轮外审太慢了,用了5个月。期间圣诞节、新年,再加上全球疫情,我们没有催稿,只能耐着性子等待:<br><br>-2021年10月14日 Preliminary Manuscript Data Submitted<br>-2021年10月15日 Author Approved Converted Files<br>-2021年10月15日 Under Review<br>-2022年03月16日 Decision Made<br>-2022年03月16日 Decision Sent to Author<br><br>第二年3月份,审稿意见回来了,大修。其中一个审稿人疑虑比较多,对我们发现的新现象持有怀疑看法,认为证据不充足,15条大意见条条有针对性;另外的审稿人稍微温和点,总体上肯定了文章的创新性,但是修改意见也不少。主编给了3个月大修时间。<br><br>几个主要作者碰头开了几次小组讨论会,制定了补试验方案,两个博士作为主力,几个硕士辅助,一直扎扎实实补试验两个月后发现deadline不够了,又向杂志申请延期1个月。三个月补完试验,一个月修改文章、图片、Response letter。我们的修回信(42页)长度超过了文章(38页)长度了,内容非常丰满,证据可靠,图片漂亮,方法全面,当时自己都觉得文章质量大幅提升,要是不接受可以投15分以上杂志了。在补试验阶段,实验材料和测试成本就花了好多w。<br><br>22年七月份投出,结果审稿人很满意,第二轮只用17天,所有审稿人均认为可以直接接受。<br><br>-2022年07月02日 Author Approved Converted Files<br>-2022年07月02日 Under Review<br>-2022年07月19日 Decision Made<br>-2022年07月19日 Decision Sent to Author<br>-2022年07月19日 With NPG, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/21/1b8a115bb4bd3136efd4521b4b663fd0.jpg, createdBy=68f11698384, createdName=Lewisrat, createdTime=Sat Jul 23 14:39:07 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085622, encodeId=739e108562226, content=10.18投稿 10.23改了一些格式重新提交, un de r review 10.26发邮件说有消息会通知 12.28状态栏出现空白 12.29又是Under Revi ew 😂稍微有点慢,这是刚送外审么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dac05542334, createdName=ms4000000644050235, createdTime=Thu Dec 30 00:25:19 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237441, encodeId=7539123e441a7, content=偏重的研究方向:细胞生物;分子医学<br>经验分享:Emm有人拒稿过吗?多久拒稿啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Mon Aug 08 22:00:09 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118088, encodeId=2339211808828, content=Research Square上能看到审稿进度。我1月31日投稿,2月17日分配编辑,3月2日邀请审稿人,邀请了两个,3月6日显示已经收到两个审稿意见。希望有个好结果🙏🏻🙏🏻🙏🏻🙏🏻, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc388334751, createdName=ms1000000326683554, createdTime=Tue Mar 07 10:55:10 CST 2023, time=2023-03-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2155649, encodeId=4f22215564929, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:生物大分子;siRNA;基础医学<br>经验分享:Stage Start Date<br>Under Review 22nd Aug 23 09:29:31<br>Author Approved Converted Files 22nd Aug 23 09:29:31<br>Preliminary Manuscript Data Submitted 22nd Aug 23 04:02:20, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af918292843, createdName=ms6000000371699092, createdTime=Fri Sep 01 20:45:42 CST 2023, time=2023-09-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1248910, encodeId=61a5124891084, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:这个杂志不是一般的慢,8月1号投稿,8月15号时候收到Associate Editor Assigned的主题邮件,到现在都没消息,都不知道送审没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0876145252, createdName=ms8000000926448182, createdTime=Wed Sep 14 17:54:42 CST 2022, time=2022-09-14, status=1, ipAttribution=)]
    2022-07-23 Lewisrat

    审稿速度:12.0 | 投稿命中率:25.0
    经验分享:21年10月投出初稿,第一轮外审太慢了,用了5个月。期间圣诞节、新年,再加上全球疫情,我们没有催稿,只能耐着性子等待:

    -2021年10月14日 Preliminary Manuscript Data Submitted
    -2021年10月15日 Author Approved Converted Files
    -2021年10月15日 Under Review
    -2022年03月16日 Decision Made
    -2022年03月16日 Decision Sent to Author

    第二年3月份,审稿意见回来了,大修。其中一个审稿人疑虑比较多,对我们发现的新现象持有怀疑看法,认为证据不充足,15条大意见条条有针对性;另外的审稿人稍微温和点,总体上肯定了文章的创新性,但是修改意见也不少。主编给了3个月大修时间。

    几个主要作者碰头开了几次小组讨论会,制定了补试验方案,两个博士作为主力,几个硕士辅助,一直扎扎实实补试验两个月后发现deadline不够了,又向杂志申请延期1个月。三个月补完试验,一个月修改文章、图片、Response letter。我们的修回信(42页)长度超过了文章(38页)长度了,内容非常丰满,证据可靠,图片漂亮,方法全面,当时自己都觉得文章质量大幅提升,要是不接受可以投15分以上杂志了。在补试验阶段,实验材料和测试成本就花了好多w。

    22年七月份投出,结果审稿人很满意,第二轮只用17天,所有审稿人均认为可以直接接受。

    -2022年07月02日 Author Approved Converted Files
    -2022年07月02日 Under Review
    -2022年07月19日 Decision Made
    -2022年07月19日 Decision Sent to Author
    -2022年07月19日 With NPG

    12

    展开12条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=1200306, encodeId=6f4c12003065f, content=收到了主题为Associate Editor Assigned的邮件,这说明到哪一阶段了??送审了没有啊???, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6cb35421011, createdName=ms1000001879726925, createdTime=Mon Mar 07 19:21:43 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106816, encodeId=035d210681669, content=请问最近有人投这个杂志吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ae45165239, createdName=146c5a24m26(暂无昵称), createdTime=Tue Dec 20 15:04:05 CST 2022, time=2022-12-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1233810, encodeId=d04112338107a, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:细胞生物;动物实验;分子医学<br>经验分享:虽然被拒了,但是感觉速度挺快的,投稿后18天得到消息。大家感兴趣的我觉得可以一试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e83e5311024, createdName=148893c2m57(暂无昵称), createdTime=Thu Jul 21 12:34:23 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100901, encodeId=8a632100901b2, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:请问这个是送审,还是还在编辑部,还没到编辑手里?有的人说没有AE assigned,有的说收到邮件了<br>Stage Start Date<br>Under Review 12th Nov 22 00:30:15<br>Author Approved Converted Files 12th Nov 22 00:30:15<br>Preliminary Manuscript Data Submitted 11th Nov 22 22:23:58, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/9d391e0b1cd74e869f11d621441146a1/0f85d4b8f25545bc8cd6ff7d737de80d.jpg, createdBy=8aaa108952, createdName=JayNi, createdTime=Wed Nov 16 16:18:50 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234254, encodeId=7a0d123425458, content=审稿速度:12.0 | 投稿命中率:25.0<br>经验分享:21年10月投出初稿,第一轮外审太慢了,用了5个月。期间圣诞节、新年,再加上全球疫情,我们没有催稿,只能耐着性子等待:<br><br>-2021年10月14日 Preliminary Manuscript Data Submitted<br>-2021年10月15日 Author Approved Converted Files<br>-2021年10月15日 Under Review<br>-2022年03月16日 Decision Made<br>-2022年03月16日 Decision Sent to Author<br><br>第二年3月份,审稿意见回来了,大修。其中一个审稿人疑虑比较多,对我们发现的新现象持有怀疑看法,认为证据不充足,15条大意见条条有针对性;另外的审稿人稍微温和点,总体上肯定了文章的创新性,但是修改意见也不少。主编给了3个月大修时间。<br><br>几个主要作者碰头开了几次小组讨论会,制定了补试验方案,两个博士作为主力,几个硕士辅助,一直扎扎实实补试验两个月后发现deadline不够了,又向杂志申请延期1个月。三个月补完试验,一个月修改文章、图片、Response letter。我们的修回信(42页)长度超过了文章(38页)长度了,内容非常丰满,证据可靠,图片漂亮,方法全面,当时自己都觉得文章质量大幅提升,要是不接受可以投15分以上杂志了。在补试验阶段,实验材料和测试成本就花了好多w。<br><br>22年七月份投出,结果审稿人很满意,第二轮只用17天,所有审稿人均认为可以直接接受。<br><br>-2022年07月02日 Author Approved Converted Files<br>-2022年07月02日 Under Review<br>-2022年07月19日 Decision Made<br>-2022年07月19日 Decision Sent to Author<br>-2022年07月19日 With NPG, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/21/1b8a115bb4bd3136efd4521b4b663fd0.jpg, createdBy=68f11698384, createdName=Lewisrat, createdTime=Sat Jul 23 14:39:07 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085622, encodeId=739e108562226, content=10.18投稿 10.23改了一些格式重新提交, un de r review 10.26发邮件说有消息会通知 12.28状态栏出现空白 12.29又是Under Revi ew 😂稍微有点慢,这是刚送外审么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dac05542334, createdName=ms4000000644050235, createdTime=Thu Dec 30 00:25:19 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237441, encodeId=7539123e441a7, content=偏重的研究方向:细胞生物;分子医学<br>经验分享:Emm有人拒稿过吗?多久拒稿啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Mon Aug 08 22:00:09 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118088, encodeId=2339211808828, content=Research Square上能看到审稿进度。我1月31日投稿,2月17日分配编辑,3月2日邀请审稿人,邀请了两个,3月6日显示已经收到两个审稿意见。希望有个好结果🙏🏻🙏🏻🙏🏻🙏🏻, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc388334751, createdName=ms1000000326683554, createdTime=Tue Mar 07 10:55:10 CST 2023, time=2023-03-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2155649, encodeId=4f22215564929, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:生物大分子;siRNA;基础医学<br>经验分享:Stage Start Date<br>Under Review 22nd Aug 23 09:29:31<br>Author Approved Converted Files 22nd Aug 23 09:29:31<br>Preliminary Manuscript Data Submitted 22nd Aug 23 04:02:20, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af918292843, createdName=ms6000000371699092, createdTime=Fri Sep 01 20:45:42 CST 2023, time=2023-09-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1248910, encodeId=61a5124891084, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:这个杂志不是一般的慢,8月1号投稿,8月15号时候收到Associate Editor Assigned的主题邮件,到现在都没消息,都不知道送审没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0876145252, createdName=ms8000000926448182, createdTime=Wed Sep 14 17:54:42 CST 2022, time=2022-09-14, status=1, ipAttribution=)]
    2021-12-30 ms4000000644050235

    10.18投稿 10.23改了一些格式重新提交, un de r review 10.26发邮件说有消息会通知 12.28状态栏出现空白 12.29又是Under Revi ew 😂稍微有点慢,这是刚送外审么

    7

    展开7条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=1200306, encodeId=6f4c12003065f, content=收到了主题为Associate Editor Assigned的邮件,这说明到哪一阶段了??送审了没有啊???, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6cb35421011, createdName=ms1000001879726925, createdTime=Mon Mar 07 19:21:43 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106816, encodeId=035d210681669, content=请问最近有人投这个杂志吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ae45165239, createdName=146c5a24m26(暂无昵称), createdTime=Tue Dec 20 15:04:05 CST 2022, time=2022-12-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1233810, encodeId=d04112338107a, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:细胞生物;动物实验;分子医学<br>经验分享:虽然被拒了,但是感觉速度挺快的,投稿后18天得到消息。大家感兴趣的我觉得可以一试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e83e5311024, createdName=148893c2m57(暂无昵称), createdTime=Thu Jul 21 12:34:23 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100901, encodeId=8a632100901b2, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:请问这个是送审,还是还在编辑部,还没到编辑手里?有的人说没有AE assigned,有的说收到邮件了<br>Stage Start Date<br>Under Review 12th Nov 22 00:30:15<br>Author Approved Converted Files 12th Nov 22 00:30:15<br>Preliminary Manuscript Data Submitted 11th Nov 22 22:23:58, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/9d391e0b1cd74e869f11d621441146a1/0f85d4b8f25545bc8cd6ff7d737de80d.jpg, createdBy=8aaa108952, createdName=JayNi, createdTime=Wed Nov 16 16:18:50 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234254, encodeId=7a0d123425458, content=审稿速度:12.0 | 投稿命中率:25.0<br>经验分享:21年10月投出初稿,第一轮外审太慢了,用了5个月。期间圣诞节、新年,再加上全球疫情,我们没有催稿,只能耐着性子等待:<br><br>-2021年10月14日 Preliminary Manuscript Data Submitted<br>-2021年10月15日 Author Approved Converted Files<br>-2021年10月15日 Under Review<br>-2022年03月16日 Decision Made<br>-2022年03月16日 Decision Sent to Author<br><br>第二年3月份,审稿意见回来了,大修。其中一个审稿人疑虑比较多,对我们发现的新现象持有怀疑看法,认为证据不充足,15条大意见条条有针对性;另外的审稿人稍微温和点,总体上肯定了文章的创新性,但是修改意见也不少。主编给了3个月大修时间。<br><br>几个主要作者碰头开了几次小组讨论会,制定了补试验方案,两个博士作为主力,几个硕士辅助,一直扎扎实实补试验两个月后发现deadline不够了,又向杂志申请延期1个月。三个月补完试验,一个月修改文章、图片、Response letter。我们的修回信(42页)长度超过了文章(38页)长度了,内容非常丰满,证据可靠,图片漂亮,方法全面,当时自己都觉得文章质量大幅提升,要是不接受可以投15分以上杂志了。在补试验阶段,实验材料和测试成本就花了好多w。<br><br>22年七月份投出,结果审稿人很满意,第二轮只用17天,所有审稿人均认为可以直接接受。<br><br>-2022年07月02日 Author Approved Converted Files<br>-2022年07月02日 Under Review<br>-2022年07月19日 Decision Made<br>-2022年07月19日 Decision Sent to Author<br>-2022年07月19日 With NPG, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/21/1b8a115bb4bd3136efd4521b4b663fd0.jpg, createdBy=68f11698384, createdName=Lewisrat, createdTime=Sat Jul 23 14:39:07 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085622, encodeId=739e108562226, content=10.18投稿 10.23改了一些格式重新提交, un de r review 10.26发邮件说有消息会通知 12.28状态栏出现空白 12.29又是Under Revi ew 😂稍微有点慢,这是刚送外审么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dac05542334, createdName=ms4000000644050235, createdTime=Thu Dec 30 00:25:19 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237441, encodeId=7539123e441a7, content=偏重的研究方向:细胞生物;分子医学<br>经验分享:Emm有人拒稿过吗?多久拒稿啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Mon Aug 08 22:00:09 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118088, encodeId=2339211808828, content=Research Square上能看到审稿进度。我1月31日投稿,2月17日分配编辑,3月2日邀请审稿人,邀请了两个,3月6日显示已经收到两个审稿意见。希望有个好结果🙏🏻🙏🏻🙏🏻🙏🏻, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc388334751, createdName=ms1000000326683554, createdTime=Tue Mar 07 10:55:10 CST 2023, time=2023-03-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2155649, encodeId=4f22215564929, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:生物大分子;siRNA;基础医学<br>经验分享:Stage Start Date<br>Under Review 22nd Aug 23 09:29:31<br>Author Approved Converted Files 22nd Aug 23 09:29:31<br>Preliminary Manuscript Data Submitted 22nd Aug 23 04:02:20, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af918292843, createdName=ms6000000371699092, createdTime=Fri Sep 01 20:45:42 CST 2023, time=2023-09-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1248910, encodeId=61a5124891084, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:这个杂志不是一般的慢,8月1号投稿,8月15号时候收到Associate Editor Assigned的主题邮件,到现在都没消息,都不知道送审没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0876145252, createdName=ms8000000926448182, createdTime=Wed Sep 14 17:54:42 CST 2022, time=2022-09-14, status=1, ipAttribution=)]
    2022-08-08 tomsyu

    偏重的研究方向:细胞生物;分子医学
    经验分享:Emm有人拒稿过吗?多久拒稿啊?

    6

    展开6条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=1200306, encodeId=6f4c12003065f, content=收到了主题为Associate Editor Assigned的邮件,这说明到哪一阶段了??送审了没有啊???, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6cb35421011, createdName=ms1000001879726925, createdTime=Mon Mar 07 19:21:43 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106816, encodeId=035d210681669, content=请问最近有人投这个杂志吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ae45165239, createdName=146c5a24m26(暂无昵称), createdTime=Tue Dec 20 15:04:05 CST 2022, time=2022-12-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1233810, encodeId=d04112338107a, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:细胞生物;动物实验;分子医学<br>经验分享:虽然被拒了,但是感觉速度挺快的,投稿后18天得到消息。大家感兴趣的我觉得可以一试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e83e5311024, createdName=148893c2m57(暂无昵称), createdTime=Thu Jul 21 12:34:23 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100901, encodeId=8a632100901b2, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:请问这个是送审,还是还在编辑部,还没到编辑手里?有的人说没有AE assigned,有的说收到邮件了<br>Stage Start Date<br>Under Review 12th Nov 22 00:30:15<br>Author Approved Converted Files 12th Nov 22 00:30:15<br>Preliminary Manuscript Data Submitted 11th Nov 22 22:23:58, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/9d391e0b1cd74e869f11d621441146a1/0f85d4b8f25545bc8cd6ff7d737de80d.jpg, createdBy=8aaa108952, createdName=JayNi, createdTime=Wed Nov 16 16:18:50 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234254, encodeId=7a0d123425458, content=审稿速度:12.0 | 投稿命中率:25.0<br>经验分享:21年10月投出初稿,第一轮外审太慢了,用了5个月。期间圣诞节、新年,再加上全球疫情,我们没有催稿,只能耐着性子等待:<br><br>-2021年10月14日 Preliminary Manuscript Data Submitted<br>-2021年10月15日 Author Approved Converted Files<br>-2021年10月15日 Under Review<br>-2022年03月16日 Decision Made<br>-2022年03月16日 Decision Sent to Author<br><br>第二年3月份,审稿意见回来了,大修。其中一个审稿人疑虑比较多,对我们发现的新现象持有怀疑看法,认为证据不充足,15条大意见条条有针对性;另外的审稿人稍微温和点,总体上肯定了文章的创新性,但是修改意见也不少。主编给了3个月大修时间。<br><br>几个主要作者碰头开了几次小组讨论会,制定了补试验方案,两个博士作为主力,几个硕士辅助,一直扎扎实实补试验两个月后发现deadline不够了,又向杂志申请延期1个月。三个月补完试验,一个月修改文章、图片、Response letter。我们的修回信(42页)长度超过了文章(38页)长度了,内容非常丰满,证据可靠,图片漂亮,方法全面,当时自己都觉得文章质量大幅提升,要是不接受可以投15分以上杂志了。在补试验阶段,实验材料和测试成本就花了好多w。<br><br>22年七月份投出,结果审稿人很满意,第二轮只用17天,所有审稿人均认为可以直接接受。<br><br>-2022年07月02日 Author Approved Converted Files<br>-2022年07月02日 Under Review<br>-2022年07月19日 Decision Made<br>-2022年07月19日 Decision Sent to Author<br>-2022年07月19日 With NPG, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/21/1b8a115bb4bd3136efd4521b4b663fd0.jpg, createdBy=68f11698384, createdName=Lewisrat, createdTime=Sat Jul 23 14:39:07 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085622, encodeId=739e108562226, content=10.18投稿 10.23改了一些格式重新提交, un de r review 10.26发邮件说有消息会通知 12.28状态栏出现空白 12.29又是Under Revi ew 😂稍微有点慢,这是刚送外审么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dac05542334, createdName=ms4000000644050235, createdTime=Thu Dec 30 00:25:19 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237441, encodeId=7539123e441a7, content=偏重的研究方向:细胞生物;分子医学<br>经验分享:Emm有人拒稿过吗?多久拒稿啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Mon Aug 08 22:00:09 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118088, encodeId=2339211808828, content=Research Square上能看到审稿进度。我1月31日投稿,2月17日分配编辑,3月2日邀请审稿人,邀请了两个,3月6日显示已经收到两个审稿意见。希望有个好结果🙏🏻🙏🏻🙏🏻🙏🏻, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc388334751, createdName=ms1000000326683554, createdTime=Tue Mar 07 10:55:10 CST 2023, time=2023-03-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2155649, encodeId=4f22215564929, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:生物大分子;siRNA;基础医学<br>经验分享:Stage Start Date<br>Under Review 22nd Aug 23 09:29:31<br>Author Approved Converted Files 22nd Aug 23 09:29:31<br>Preliminary Manuscript Data Submitted 22nd Aug 23 04:02:20, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af918292843, createdName=ms6000000371699092, createdTime=Fri Sep 01 20:45:42 CST 2023, time=2023-09-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1248910, encodeId=61a5124891084, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:这个杂志不是一般的慢,8月1号投稿,8月15号时候收到Associate Editor Assigned的主题邮件,到现在都没消息,都不知道送审没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0876145252, createdName=ms8000000926448182, createdTime=Wed Sep 14 17:54:42 CST 2022, time=2022-09-14, status=1, ipAttribution=)]
    2023-03-07 ms1000000326683554 来自江苏省

    Research Square上能看到审稿进度。我1月31日投稿,2月17日分配编辑,3月2日邀请审稿人,邀请了两个,3月6日显示已经收到两个审稿意见。希望有个好结果🙏🏻🙏🏻🙏🏻🙏🏻

    5

    展开5条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=1200306, encodeId=6f4c12003065f, content=收到了主题为Associate Editor Assigned的邮件,这说明到哪一阶段了??送审了没有啊???, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6cb35421011, createdName=ms1000001879726925, createdTime=Mon Mar 07 19:21:43 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106816, encodeId=035d210681669, content=请问最近有人投这个杂志吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ae45165239, createdName=146c5a24m26(暂无昵称), createdTime=Tue Dec 20 15:04:05 CST 2022, time=2022-12-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1233810, encodeId=d04112338107a, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:细胞生物;动物实验;分子医学<br>经验分享:虽然被拒了,但是感觉速度挺快的,投稿后18天得到消息。大家感兴趣的我觉得可以一试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e83e5311024, createdName=148893c2m57(暂无昵称), createdTime=Thu Jul 21 12:34:23 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100901, encodeId=8a632100901b2, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:请问这个是送审,还是还在编辑部,还没到编辑手里?有的人说没有AE assigned,有的说收到邮件了<br>Stage Start Date<br>Under Review 12th Nov 22 00:30:15<br>Author Approved Converted Files 12th Nov 22 00:30:15<br>Preliminary Manuscript Data Submitted 11th Nov 22 22:23:58, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/9d391e0b1cd74e869f11d621441146a1/0f85d4b8f25545bc8cd6ff7d737de80d.jpg, createdBy=8aaa108952, createdName=JayNi, createdTime=Wed Nov 16 16:18:50 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234254, encodeId=7a0d123425458, content=审稿速度:12.0 | 投稿命中率:25.0<br>经验分享:21年10月投出初稿,第一轮外审太慢了,用了5个月。期间圣诞节、新年,再加上全球疫情,我们没有催稿,只能耐着性子等待:<br><br>-2021年10月14日 Preliminary Manuscript Data Submitted<br>-2021年10月15日 Author Approved Converted Files<br>-2021年10月15日 Under Review<br>-2022年03月16日 Decision Made<br>-2022年03月16日 Decision Sent to Author<br><br>第二年3月份,审稿意见回来了,大修。其中一个审稿人疑虑比较多,对我们发现的新现象持有怀疑看法,认为证据不充足,15条大意见条条有针对性;另外的审稿人稍微温和点,总体上肯定了文章的创新性,但是修改意见也不少。主编给了3个月大修时间。<br><br>几个主要作者碰头开了几次小组讨论会,制定了补试验方案,两个博士作为主力,几个硕士辅助,一直扎扎实实补试验两个月后发现deadline不够了,又向杂志申请延期1个月。三个月补完试验,一个月修改文章、图片、Response letter。我们的修回信(42页)长度超过了文章(38页)长度了,内容非常丰满,证据可靠,图片漂亮,方法全面,当时自己都觉得文章质量大幅提升,要是不接受可以投15分以上杂志了。在补试验阶段,实验材料和测试成本就花了好多w。<br><br>22年七月份投出,结果审稿人很满意,第二轮只用17天,所有审稿人均认为可以直接接受。<br><br>-2022年07月02日 Author Approved Converted Files<br>-2022年07月02日 Under Review<br>-2022年07月19日 Decision Made<br>-2022年07月19日 Decision Sent to Author<br>-2022年07月19日 With NPG, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/21/1b8a115bb4bd3136efd4521b4b663fd0.jpg, createdBy=68f11698384, createdName=Lewisrat, createdTime=Sat Jul 23 14:39:07 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085622, encodeId=739e108562226, content=10.18投稿 10.23改了一些格式重新提交, un de r review 10.26发邮件说有消息会通知 12.28状态栏出现空白 12.29又是Under Revi ew 😂稍微有点慢,这是刚送外审么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dac05542334, createdName=ms4000000644050235, createdTime=Thu Dec 30 00:25:19 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237441, encodeId=7539123e441a7, content=偏重的研究方向:细胞生物;分子医学<br>经验分享:Emm有人拒稿过吗?多久拒稿啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Mon Aug 08 22:00:09 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118088, encodeId=2339211808828, content=Research Square上能看到审稿进度。我1月31日投稿,2月17日分配编辑,3月2日邀请审稿人,邀请了两个,3月6日显示已经收到两个审稿意见。希望有个好结果🙏🏻🙏🏻🙏🏻🙏🏻, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc388334751, createdName=ms1000000326683554, createdTime=Tue Mar 07 10:55:10 CST 2023, time=2023-03-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2155649, encodeId=4f22215564929, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:生物大分子;siRNA;基础医学<br>经验分享:Stage Start Date<br>Under Review 22nd Aug 23 09:29:31<br>Author Approved Converted Files 22nd Aug 23 09:29:31<br>Preliminary Manuscript Data Submitted 22nd Aug 23 04:02:20, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af918292843, createdName=ms6000000371699092, createdTime=Fri Sep 01 20:45:42 CST 2023, time=2023-09-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1248910, encodeId=61a5124891084, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:这个杂志不是一般的慢,8月1号投稿,8月15号时候收到Associate Editor Assigned的主题邮件,到现在都没消息,都不知道送审没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0876145252, createdName=ms8000000926448182, createdTime=Wed Sep 14 17:54:42 CST 2022, time=2022-09-14, status=1, ipAttribution=)]
    2023-09-01 ms6000000371699092 来自上海

    审稿速度:1.0 | 投稿命中率:25.0
    偏重的研究方向:生物大分子;siRNA;基础医学
    经验分享:Stage Start Date
    Under Review 22nd Aug 23 09:29:31
    Author Approved Converted Files 22nd Aug 23 09:29:31
    Preliminary Manuscript Data Submitted 22nd Aug 23 04:02:20

    4

    展开4条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=1200306, encodeId=6f4c12003065f, content=收到了主题为Associate Editor Assigned的邮件,这说明到哪一阶段了??送审了没有啊???, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6cb35421011, createdName=ms1000001879726925, createdTime=Mon Mar 07 19:21:43 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106816, encodeId=035d210681669, content=请问最近有人投这个杂志吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ae45165239, createdName=146c5a24m26(暂无昵称), createdTime=Tue Dec 20 15:04:05 CST 2022, time=2022-12-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1233810, encodeId=d04112338107a, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:细胞生物;动物实验;分子医学<br>经验分享:虽然被拒了,但是感觉速度挺快的,投稿后18天得到消息。大家感兴趣的我觉得可以一试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e83e5311024, createdName=148893c2m57(暂无昵称), createdTime=Thu Jul 21 12:34:23 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100901, encodeId=8a632100901b2, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:请问这个是送审,还是还在编辑部,还没到编辑手里?有的人说没有AE assigned,有的说收到邮件了<br>Stage Start Date<br>Under Review 12th Nov 22 00:30:15<br>Author Approved Converted Files 12th Nov 22 00:30:15<br>Preliminary Manuscript Data Submitted 11th Nov 22 22:23:58, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/9d391e0b1cd74e869f11d621441146a1/0f85d4b8f25545bc8cd6ff7d737de80d.jpg, createdBy=8aaa108952, createdName=JayNi, createdTime=Wed Nov 16 16:18:50 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234254, encodeId=7a0d123425458, content=审稿速度:12.0 | 投稿命中率:25.0<br>经验分享:21年10月投出初稿,第一轮外审太慢了,用了5个月。期间圣诞节、新年,再加上全球疫情,我们没有催稿,只能耐着性子等待:<br><br>-2021年10月14日 Preliminary Manuscript Data Submitted<br>-2021年10月15日 Author Approved Converted Files<br>-2021年10月15日 Under Review<br>-2022年03月16日 Decision Made<br>-2022年03月16日 Decision Sent to Author<br><br>第二年3月份,审稿意见回来了,大修。其中一个审稿人疑虑比较多,对我们发现的新现象持有怀疑看法,认为证据不充足,15条大意见条条有针对性;另外的审稿人稍微温和点,总体上肯定了文章的创新性,但是修改意见也不少。主编给了3个月大修时间。<br><br>几个主要作者碰头开了几次小组讨论会,制定了补试验方案,两个博士作为主力,几个硕士辅助,一直扎扎实实补试验两个月后发现deadline不够了,又向杂志申请延期1个月。三个月补完试验,一个月修改文章、图片、Response letter。我们的修回信(42页)长度超过了文章(38页)长度了,内容非常丰满,证据可靠,图片漂亮,方法全面,当时自己都觉得文章质量大幅提升,要是不接受可以投15分以上杂志了。在补试验阶段,实验材料和测试成本就花了好多w。<br><br>22年七月份投出,结果审稿人很满意,第二轮只用17天,所有审稿人均认为可以直接接受。<br><br>-2022年07月02日 Author Approved Converted Files<br>-2022年07月02日 Under Review<br>-2022年07月19日 Decision Made<br>-2022年07月19日 Decision Sent to Author<br>-2022年07月19日 With NPG, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/21/1b8a115bb4bd3136efd4521b4b663fd0.jpg, createdBy=68f11698384, createdName=Lewisrat, createdTime=Sat Jul 23 14:39:07 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085622, encodeId=739e108562226, content=10.18投稿 10.23改了一些格式重新提交, un de r review 10.26发邮件说有消息会通知 12.28状态栏出现空白 12.29又是Under Revi ew 😂稍微有点慢,这是刚送外审么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dac05542334, createdName=ms4000000644050235, createdTime=Thu Dec 30 00:25:19 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237441, encodeId=7539123e441a7, content=偏重的研究方向:细胞生物;分子医学<br>经验分享:Emm有人拒稿过吗?多久拒稿啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Mon Aug 08 22:00:09 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118088, encodeId=2339211808828, content=Research Square上能看到审稿进度。我1月31日投稿,2月17日分配编辑,3月2日邀请审稿人,邀请了两个,3月6日显示已经收到两个审稿意见。希望有个好结果🙏🏻🙏🏻🙏🏻🙏🏻, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc388334751, createdName=ms1000000326683554, createdTime=Tue Mar 07 10:55:10 CST 2023, time=2023-03-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2155649, encodeId=4f22215564929, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:生物大分子;siRNA;基础医学<br>经验分享:Stage Start Date<br>Under Review 22nd Aug 23 09:29:31<br>Author Approved Converted Files 22nd Aug 23 09:29:31<br>Preliminary Manuscript Data Submitted 22nd Aug 23 04:02:20, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af918292843, createdName=ms6000000371699092, createdTime=Fri Sep 01 20:45:42 CST 2023, time=2023-09-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1248910, encodeId=61a5124891084, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:这个杂志不是一般的慢,8月1号投稿,8月15号时候收到Associate Editor Assigned的主题邮件,到现在都没消息,都不知道送审没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0876145252, createdName=ms8000000926448182, createdTime=Wed Sep 14 17:54:42 CST 2022, time=2022-09-14, status=1, ipAttribution=)]
    2022-09-14 ms8000000926448182

    审稿速度:3.0 | 投稿命中率:50.0
    经验分享:这个杂志不是一般的慢,8月1号投稿,8月15号时候收到Associate Editor Assigned的主题邮件,到现在都没消息,都不知道送审没有

    4

    展开4条回复
共256条页码: 1/26页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分